Wells Fargo & Company MN Sells 117,892 Shares of Bausch Health Companies Inc (NYSE:BHC)

Wells Fargo & Company MN reduced its position in shares of Bausch Health Companies Inc (NYSE:BHC) by 56.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 91,626 shares of the company’s stock after selling 117,892 shares during the quarter. Wells Fargo & Company MN’s holdings in Bausch Health Companies were worth $2,311,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. FIL Ltd grew its holdings in shares of Bausch Health Companies by 69.6% during the first quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after purchasing an additional 4,327,851 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Bausch Health Companies by 0.5% during the first quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock worth $71,563,000 after purchasing an additional 14,610 shares during the last quarter. Ardevora Asset Management LLP grew its holdings in shares of Bausch Health Companies by 23.8% during the second quarter. Ardevora Asset Management LLP now owns 1,788,520 shares of the company’s stock worth $45,106,000 after purchasing an additional 343,900 shares during the last quarter. Swiss National Bank grew its holdings in shares of Bausch Health Companies by 5.6% during the second quarter. Swiss National Bank now owns 1,165,060 shares of the company’s stock worth $29,392,000 after purchasing an additional 62,100 shares during the last quarter. Finally, AJO LP lifted its stake in shares of Bausch Health Companies by 21.3% in the first quarter. AJO LP now owns 877,074 shares of the company’s stock worth $21,664,000 after acquiring an additional 153,945 shares during the period. Institutional investors own 56.04% of the company’s stock.

BHC traded down $0.04 during trading on Wednesday, hitting $21.99. The company’s stock had a trading volume of 2,444,939 shares, compared to its average volume of 2,574,916. Bausch Health Companies Inc has a twelve month low of $17.20 and a twelve month high of $28.45. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 8.94. The stock’s fifty day moving average price is $22.11 and its 200-day moving average price is $23.44. The firm has a market capitalization of $8.04 billion, a P/E ratio of 5.47 and a beta of 0.80.



Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same period last year, the firm posted $0.93 earnings per share. Bausch Health Companies’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities research analysts expect that Bausch Health Companies Inc will post 4.25 EPS for the current fiscal year.

In other Bausch Health Companies news, EVP Christina Ackermann sold 3,968 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $24.81, for a total value of $98,446.08. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William D. Humphries purchased 30,703 shares of the company’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $21.18 per share, for a total transaction of $650,289.54. The disclosure for this purchase can be found here. Over the last three months, insiders sold 18,159 shares of company stock worth $410,355. Insiders own 11.87% of the company’s stock.

BHC has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on Bausch Health Companies from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Wolfe Research initiated coverage on Bausch Health Companies in a research note on Friday, July 19th. They issued an “outperform” rating and a $31.00 price objective on the stock. Cantor Fitzgerald set a $32.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a research note on Friday, May 31st. Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Finally, Barclays set a $28.00 price objective on Bausch Health Companies and gave the stock a “buy” rating in a research note on Monday, July 8th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the stock. Bausch Health Companies has an average rating of “Buy” and an average target price of $29.68.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Story: Support Level

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.